Addition of a sodium-glucose cotransporter-2 (SGLT2) inhibitor, either dapagliflozin or empagliflozin (1), has been shown to reduce morbidity and mortality when added to standard care in patients with elevated natriuretic peptide levels; benefit was similar in patients with and without diabetes.